Recommendations for Screening and Diagnosis of Chagas Disease in the United States

U.S. Chagas Diagnostic Working Group, Colin J. Forsyth1*, Jennifer Manne-Goehler2**, Caryn Bern3, Jeffrey Whitman4, Natasha S. Hochberg5, Morven Edwards6, Rachel Marcus7, Norman L. Beatty8, Yagahira Castro9, Christina Coyle10, Paula Stigler-Granados11, Davidson Hamer12, James H. Maguire13, Robert Gilman9, Sheba Meymandi14

*=corresponding author (40 Rector Street, 16th Floor New York, NY 10006 USA, cforsyth@dndi.org)

**=alternate corresponding author (75 Francis St, Boston, MA 02115, jen.manne@gmail.com)

1. Drugs for Neglected Diseases initiative, New York, New York, USA. cforsyth@dndi.org
2. Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
3. Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA
4. Department of Laboratory Medicine, University of California, San Francisco, San Francisco, California, USA
5. Department of Medicine, Section of Infectious Diseases, Boston University School of Medicine, and Department of Epidemiology, Boston University School of Public Health, Boston, Massachusetts, USA
6. Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA
7. Medstar Union Memorial Hospital and LASOCHA, Washington, DC, USA
8. Division of Infectious Diseases and Global Medicine, University of Florida College of Medicine, Gainesville, Florida, USA
9. Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
10. Division of Infectious Diseases, Albert Einstein College of Medicine and Jacobi Medical Center, Bronx, New York, USA
11. School of Health Administration, Texas State University, San Marcos, Texas, USA
12. Department of Global Health, Boston University School of Public Health and Section of Infectious Diseases, Boston University School of Medicine, Boston, Massachusetts, USA
13. Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA

© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Summary: This article provides recommendations for screening and diagnosis of Chagas disease in the United States, including identification of the population at risk in community or clinical settings, diagnosis of chronic and congenital infection, and next steps following confirmed diagnosis.
Abstract

**Background:** Chagas disease affects an estimated 326,000-347,000 people in the United States and is severely underdiagnosed. Lack of awareness and clarity regarding screening and diagnosis is a key barrier.

**Objective:** This document provides straightforward recommendations, with the goal of simplifying identification and testing of people at risk for U.S. healthcare providers.

**Methods:** A multidisciplinary working group of clinicians and researchers with expertise in Chagas disease agreed on six main questions, and developed recommendations based on the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology, after reviewing the relevant literature on Chagas disease in the United States.

**Results:** Individuals who were born or resided for prolonged time periods in endemic countries of Mexico, Central and South America should be tested for *T. cruzi* infection, and family members of people who test positive should be screened. Women of childbearing age with risk factors and infants born to seropositive mothers deserve special consideration due to the risk of vertical transmission. Diagnostic testing for chronic *T. cruzi* infection should be conducted using two distinct assays.

**Conclusions:** Increasing provider-directed screening for *T. cruzi* infection is key to addressing this neglected public health challenge in the United States.

**Key words:** Chagas disease; *Trypanosoma cruzi*; diagnosis; neglected diseases.
Introduction/Background

Chagas disease (CD) is a neglected tropical disease of substantial public health importance. In the United States, > 300,000 people are estimated to be infected with Trypanosoma cruzi, the protozoan that causes the disease [1, 2]. The vast majority were infected while living in endemic areas of Latin America and are in a chronic phase of the disease. While most remain asymptomatic for life, 20-30% eventually develop Chagas cardiomyopathy, and up to 10% may suffer damage to the gastrointestinal or nervous systems [3]. CD causes a heavy burden of morbidity and mortality, resulting in an estimated global annual loss of >800,000 disability-adjusted life-years, including >27,000 annually in the U.S. [4]. Only about 1% of estimated U.S. cases have been identified, usually through blood donor screening [5]. Most people are unaware they are infected with T. cruzi. Provider-directed screening is essential since early diagnosis and treatment can improve outcomes and limit mother-to-child transmission. Screening programs for CD are highly cost effective[6], but with the current paradigm of limited testing, estimated total annual healthcare costs from CD in the U.S. exceed $130,000,000 [4]. However, not all U.S. providers are aware of CD [7], and testing poses certain challenges.

The Pan American Health Organization has provided overall guidelines on diagnosis and management of CD [8]. The United States Centers for Disease Control’s website also provides specific recommendations for healthcare providers [9-11]. Here we examine considerations for screening and diagnosis of CD in the U.S.

Methods

A group of experts on CD screening and management in the U.S., including clinicians, researchers, and public health experts, prepared these recommendations. Group members had previously participated in meetings on challenges in diagnosis of CD. The working group was organized to provide a straightforward, quick-reference tool to facilitate CD testing by primary healthcare providers, hospitals, infectious disease specialists, and laboratories. Diagnostic guidance was constructed via both expert consensus and the GRADE methodology [12]. The group agreed on six main questions based on the PICO method (Population, Intervention, Comparison, and Outcome) and divided into subgroups to discuss each and propose initial recommendations, which were then shared and validated within the larger group. Literature searches were conducted on CD screening and prevalence in the U.S. and the four assays that are currently Food and Drug Administration (FDA)-cleared for clinical use (Supplementary Table 1).

The GRADE methodology provides two types of ratings. The strength of the recommendation (strong or conditional, either for or against a recommendation) is based on the public health priority, potential benefit, feasibility of implementation, acceptability to patients, and costs in terms of resources. An additional rating is provided for the quality of available evidence supporting the recommendation (high, moderate, low, very low), which considers previous study designs, effect size, relevance, sources of bias, and other factors. Two key limitations should be noted: 1) the evidence on U.S. CD has significant gaps, and 2) while the GRADE methodology provides a structured, evidence-based framework, this does not completely rule out subjectivity in determining ratings.
Results

I. Who should be screened for Chagas disease in the United States?

a. Are there populations at risk that should be screened?

Recommendations.

i. Screening people who were born or lived for a prolonged period (>6 months) in areas of Mexico, Central or South America with endemic Chagas disease can effectively identify new cases. (strong, low)

Within the U.S. population, people who were born or lived for a prolonged period in areas with endemic CD in Mexico, Central, or South America are at greatest risk of T. cruzi infection (Table 1). One community-based study of over 4,000 Latin-American born immigrants living in Los Angeles showed a seroprevalence of 1.24% [13]. Among people who were born or lived for a prolonged period in Latin America, the seroprevalence has been higher still in those with evidence of characteristic findings on electrocardiogram (ECG) including bundle-branch blocks, non-ischemic cardiomyopathy or pacemaker placement [14-17]. This supports the assertion that screening people who were born or lived for a prolonged period in areas with endemic Chagas disease – Mexico, Central and South America – is a viable approach to identifying new cases. Generally, people will need to be screened even though they do not exhibit visible signs or symptoms of CD.

ii. Screening close (first-degree) relatives of people previously diagnosed with Chagas disease can effectively identify new cases. (strong, low)

Limited evidence shows a substantial prevalence of T. cruzi infection among close relatives of people previously diagnosed with CD. A Los Angeles study found a prevalence of 7.4% among family members of CD patients [18]. Screening the relatives of people who have been previously diagnosed with the disease is another way to identify individuals with CD. When a patient is confirmed positive, healthcare providers should encourage the patient to advise family members to seek testing. (Contact information for U.S. providers with expertise in Chagas disease can be found at https://uschagasnetwork.org/providers).

iii. Screening people with documented exposure to triatomines, in states with known presence of triatomin species capable of transmitting T. cruzi. (conditional, low)

Autochthonous transmission can occur in the U.S., with cases reported in at least eight states as of 2020. Most confirmed or suspected autochthonous cases were detected via screening of blood donors, and often these cases face barriers to obtaining treatment [19, 20]. Triatomines (kissing bugs) have been identified in 29 states in the southern U.S. and limited studies have shown that most can harbor T. cruzi at varying rates [21, 22]. Some infected triatomines feed on humans, based on the finding of human blood in their gut [22, 23]. Since autochthonous transmission has been demonstrated and naturally infected triatomines reside in the U.S., screening people who have highly suspected exposure to triatomines (e.g., entomological confirmation of triatomines in the home) in states where the vector is known to reside is a reasonable approach to identifying potential cases of autochthonous CD [24].
iv. Travelers to endemic regions of Latin America

Travelers with confirmed exposure to triatomines or associated risk factors in regions of Latin America where Chagas disease is endemic may be tested to rule out possible *T. cruzi* infection (conditional, low).

Acquisition of CD is thought to occur rarely among travelers, but evidence is limited. Risk factors for travel-acquired CD include: confirmed or suspected exposures to triatomines, staying in a rural setting in housing constructed of mud, adobe, thatch, or other natural materials, and consumption of raw or unpasteurized food or beverages, such as sugar cane extract, guava and bacaba juice, açaí pulp, or palm wine [25]. Such travelers may have non-specific symptoms including fever, malaise and myalgias; acute CD should be considered in addition to other infectious diseases. We advise travel medicine specialists to consider the risk and include advice on preventive measures for individuals with high-risk travel that might expose them to the *T. cruzi* vector.

Ib. Should women of childbearing age from Latin America be screened?

*Recommendation.*

Screening women of childbearing age who have lived in a region of Mexico, South or Central America with endemic Chagas disease can effectively identify cases and prevent congenital transmission of the disease. (Strong, moderate)

Congenital transmission of CD from infected mother to unborn child is a potentially important mode of disease transmission in the U.S. Several U.S. surveys in pregnant women from high-risk groups have shown a substantial prevalence of *T. cruzi* infection (Table 2). From a public health perspective, treatment of women before pregnancy can prevent congenital transmission and provide health benefits for the mother [26]. Targeted and universal screening for CD in U.S. mothers is cost-saving for all rates of congenital transmission >0.001% and all levels of maternal prevalence >0.06%, compared with no screening [6].

II. Which clinical conditions warrant diagnostic testing for Chagas disease in people from endemic countries of Latin America?

*Recommendation.*

*T. cruzi* serologic testing should be performed in individuals with epidemiological risk factors who present with the following clinical syndromes:

a. Electrocardiographic abnormalities suggestive of infection, even in the absence of symptoms.

These include first degree atrioventricular block, premature ventricular contractions, atrial
fibrillation, right bundle branch block, left anterior fascicular block, bifascicular block, and low voltage QRS. (Strong, low)

b. Bradyarrhythmias (Strong, low)

c. Tachyarrhythmias (atrial fibrillation/ventricular tachycardia), including sudden cardiac death (Strong, low)

d. Regional wall motion abnormalities (particularly basal inferolateral, apical aneurysm) (Strong, low)

e. Thromboembolic phenomenon (Strong, low)

f. Congestive heart failure and/or a reduced ejection fraction. (Strong, low)

g. Megacolon/megaesophagus (Strong, low)

Screening Latin American-born individuals with the above syndromes for CD has ramifications for the evaluation, treatment, and prognosis of the individual. Because of limited screening for CD in the U.S. and profound healthcare barriers for the at-risk population, many individuals with CD first receive medical attention after developing a clinical syndrome of the illness. However, estimates suggest <1% of people with signs/symptoms suggestive of CD actually receive CD testing [27]. An estimated 30,000-45,000 people in the U.S. suffer from CD cardiomyopathy [2]. In two small studies of Latin American-born patients with nonischemic cardiomyopathy, 5/39 in a New York hospital and 26/135 in a Los Angeles hospital network were seropositive for T. cruzi infection [14, 17]. Other Los Angeles studies in Latin American-born patients found a prevalence of 7.5% among those with pacemakers and 5.2% in those with conduction abnormalities [15, 16].

h. Screening and diagnosis in immunosuppressed patients

Immunosuppressed hosts with acute T. cruzi infection (e.g., donor-derived infection) are at risk for severe manifestations such as meningoencephalitis or acute myocarditis. Recipients of blood components, organ or tissue from an infected donor should be monitored by serial polymerase chain reaction (PCR) in blood weekly during months 1-2, every 2 weeks during months 3-4, monthly during months 5-6 post transfusion or transplant, then based on the clinical scenario [10].

Immunosuppression in an individual with chronic T. cruzi infection may lead to reactivation, characterized by a return to high levels of parasitemia. In transplant recipients, manifestations of reactivation vary depending on host characteristics and immunosuppressive regimen; reactivation myocarditis can be life-threatening. A positive PCR result does not constitute a diagnosis of reactivation, since this occurs in patients with chronic infection in the absence of reactivation. Serial monitoring by quantitative PCR, using a schedule similar to that outlined above, provides early detection of reactivation based on falling cycle threshold (Ct) values, reflecting rising parasite loads [28, 29]. The US CDC
provides consultation on the management of patients and acts as a reference laboratory to monitor for reactivation by serial PCR. The most common manifestations of reactivation in HIV-T. cruzi co-infected patients include central nervous system (CNS) mass lesions, with or without meningoencephalitis, and myocarditis. Diagnosis varies depending on the clinical scenario; in CNS reactivation, parasites may be detectable by microscopy or PCR of cerebrospinal fluid.

III. What is the diagnostic algorithm for testing neonates and infants (<1 year old) who are born to infected mothers?

Recommendation

Infants in whom congenital Chagas disease is suspected should undergo evaluation using existing Centers for Disease Control-based recommendations (Strong; moderate)

Edwards et al 2019 provides a comprehensive review of diagnosis and treatment of congenital Chagas disease that is [11] summarized below. Infants born to women with suspected or confirmed CD, and infants with clinical features of congenital infection born to women at risk for CD, should undergo evaluation as soon as possible after birth to detect hepatomegaly, splenomegaly, anemia or thrombocytopenia and, as indicated, pneumonitis, heart failure, cardiac arrhythmia or meningoencephalitis. (Figure 1) [11, 30, 31] The cure rate for treatment in the first year of infection exceeds 90%, and treatment is well-tolerated [30, 32, 33].

If the mother’s infection status is unknown, serologic testing for Trypanosoma cruzi IgG antibodies should be performed to determine infant risk. Diagnosis of congenital infection relies on detection of motile trypomastigotes through microscopic examination of a wet mount of fresh anticoagulated blood or buffy coat specimen (collected in microhematocrit tube), detection of parasites on Giemsa-stained blood smears and/or PCR testing for T. cruzi DNA in whole blood from the infant. This testing is available through the Parasitic Diseases Reference Laboratory at the CDC. Histopathologic examination of the umbilical cord and examination of cerebrospinal fluid in at-risk infants with meningoencephalitis may also reveal the parasite (43). Since maternal blood contamination has been reported in a small number of infants born to infected mothers, a positive PCR result in an infant should be confirmed by repeat testing (Figure 1). If a second PCR is positive, the diagnosis of congenital CD is confirmed and the infant should undergo clinical evaluation for features of congenital CD, such as cardiac arrhythmias, laboratory evaluation, and initiation of treatment. For mothers who are seropositive for T. cruzi infection whose infants are PCR negative, infants should undergo repeat testing at 4 to 6 weeks of age to confirm absence of infection [34, 35].

Because parasitemia levels can fluctuate, the serologic status of infants born to mothers with chronic CD should be monitored even if the infant has negative PCR results early in life. Transferred maternal IgG antibodies persist in infants for up to 12 months [36, 37]. If an infant first evaluated at 3 months of age or older has a positive CD screening T. cruzi IgG test, performed through a commercial laboratory, repeat screening should be performed when the infant reaches 9 to 12 months of age. If antibody remains detectable, confirmatory serologic testing through CDC is appropriate to establish or exclude congenital
infection (Figure 2) [30]. An increase in antibody titer over time after 9 months of age, documented at CDC, indicates congenital infection.

IV. What is the recommended algorithm for diagnosing Chagas disease in the United States?

Recommendations.

a. Diagnostic testing for chronic *T. cruzi* infection should be conducted using two distinct assays, based on different antigens or in different formats, following Pan American Health Organization (PAHO) and CDC guidelines. If the results are discordant, a third distinct test should be performed. Confirmed diagnosis requires positive results by at least two tests (Strong, moderate)

b. Screening by clinical and public health laboratories in populations with low *T. cruzi* infection prevalence should be conducted using a high sensitivity test, bearing in mind the anticipated false positive rate of (1 – specificity). Individuals with positive results by the screening test require confirmatory testing as outlined in the above recommendation (Strong, moderate)

Confirmation of chronic *T. cruzi* infection requires positive results by two different tests, preferably based on different antigens, to optimize sensitivity and specificity [8]. However, most commercial laboratories in the U.S. only utilize one assay. If positive based on commercial laboratory results, sending samples to CDC for confirmation assures that the criteria of two distinct assays is met. More confirmatory testing options may become available in the future. Clinicians should check with their healthcare system’s clinical laboratory for current or preferred confirmatory testing options.

Providers can contact CDC with questions about Chagas disease (parasites@cdc.gov, 404-718-4745). Requests for CDC testing should be coordinated with the state or local health department.

c. FDA-cleared serological tests for Chagas disease

Four IgG serological tests have FDA clearance for diagnosis of chronic *T. cruzi* infection (Table 4), two *T. cruzi* lysate-based enzyme-linked immunoassays (ELISAs): the Ortho *T. cruzi* ELISA and Hemagen Chagas’ kit ELISA; one recombinant antigen-based ELISA:Wiener Chagatest Recombinante 3.0; and a recombinant antigen-based immunochromatographic strip test: InBios Chagas Detect Plus. All four tests have high manufacturer-reported sensitivity and specificity, but post-clearance performance data are
sparse, especially in U.S. resident populations (Supplementary Table 1). In U.S.-based evaluations, the Wiener Chagatest Recombinante 3.0 assay consistently showed high specificity and intermediate sensitivity [38-40]. Investigations also confirm variation in assay performance by geographic origin of infections, with sensitivity generally highest in specimens from South America, intermediate in Central America and lowest in those from Mexico, Panama and southern Peru [38, 40-43]. These differences are often attributed to T. cruzi genetic differences, but do not correlate entirely with the predominant lineages as currently identified [44]. Further diagnostic test evaluations in robust sets of specimens from at-risk U.S. populations are needed to provide an adequate evidence base for recommendations for use of specific assays.

However, prospective parallel testing by multiple assays in population-level screening may be prohibitively expensive. In a serial testing scenario the population is screened by a single test and only those with positive results receive a second, confirmatory test; when the results are discordant, a third test is used as tie-breaker. Algorithms should be designed with test performance characteristics in mind; a deliberate choice must be made regarding the acceptable number of missed infections versus the cost of additional testing (and the logistics of having patients return for testing) required to rule out false positives. Figure 3 provides a basic framework of the testing process, from identification of risk factors to diagnostic confirmation.

V. What is the appropriate course of action if the screening and confirmatory tests for Chagas disease are discordant?

The lack of a ‘gold standard’ CD test necessitates multi-step serological testing to confirm chronic T. cruzi infection. Discordant test results can be expected due to imperfect test performance and will be a large proportion of total results given CD’s overall low prevalence in the US. When the results of the first two assays are discordant, a third test is required to assign a consensus positive or negative status for the presence of IgG antibodies to T. cruzi in the individual.

Diagnostic serologic testing in the US is primarily available at commercial reference laboratories and CDC. Currently, CDC performs an ELISA (Chagatest Recombinante v.3.0; Wiener Laboratories, Rosario, Argentina) and an immunoblot using trypomastigote excreted-secreted antigens (TESA) when Chagas disease serology is requested. If results are discordant, a second sample is requested; if results are again discordant, a third serologic test is run (immunofluorescence assay [IFA] based on slide-fixed epimastigotes) [45, 46]. At CDC, the TESA and IFA assays are laboratory developed tests and all tests are run under the Clinical Laboratory Improvement Amendments (CLIA). Currently, FDA does not clear or approve laboratory developed tests [47], but their validation and performance is reviewed during laboratory inspections to maintain CLIA certification. There are no published diagnostic evaluations for the CDC TESA and IFA tests in infected populations of the US, but these test formats have been widely used throughout Latin America.

Most testing currently begins with a commercial laboratory, where typically only one IgG assay is used. Commercial laboratories periodically change the tests they employ due to commercial availability, cost, and testing format and performance. To ensure that two different serologic assays are used, it will be
necessary to confirm which assay is being performed. In general, a sample should then be sent to CDC for confirmation.

VI. What is the next step after a patient has a confirmed diagnosis of Chagas disease?

Recommendation.

Even if asymptomatic, individuals who test positive for *T. cruzi* infection should receive:

a. **Electrocardiogram (strong, high)**

b. **Echocardiogram (strong, low)**

c. **Chest X-ray, if an echocardiogram is unavailable (conditional, low)**

Individuals with *T. cruzi* infection may have no evidence of organ involvement (indeterminate form) or organ involvement with or without noticeable symptoms. Individuals with any of these forms would be expected to be seropositive. Determining whether the patient has the indeterminate form of CD or has progressed to Chagas cardiomyopathy or other end-organ involvement is important for establishing a treatment plan. A normal echocardiogram and electrocardiogram (ECG) indicate an indeterminate form of CD [48]. (In settings where an echocardiogram is not available, a chest X-ray may be considered instead.) The ECG should be repeated annually to detect signs of progression to Chagas cardiomyopathy, even in individuals who receive antitrypanosomal treatment [48]. Echocardiogram may be repeated depending on the patient’s clinical status. Those with cardiac symptoms and/or abnormalities on one or more of the above tests should be referred to a cardiologist for more extensive testing [49]. Patients with immunosuppressive conditions require special consideration due to the risk of reactivation and should be referred to an infectious disease specialist. Patients from southern Cone countries of South America (Argentina, Bolivia, Brazil, Chile, and Paraguay) may be more at risk for gastrointestinal complications. Steps for diagnosis and management of gastrointestinal CD are provided by Pinazo et al. [50].

Discussion

Uncertainties and complexities around current CD testing processes in the U.S. pose a major barrier to increasing screening coverage, perpetuating a situation where <1% of the estimated population with the disease has been tested. This document provides clear, straightforward guidance to healthcare personnel to facilitate screening and diagnosis of the people at risk, so that they can receive timely and appropriate care. While more research is needed, both on the epidemiology of CD in the U.S., including congenital and vector-borne transmission and the burden of disease in specific populations, and on the performance of diagnostic tools in the heterogeneous U.S. patient population, this document presents practical recommendations based on the best information currently available. Ensuring proactive screening of patients will require concerted efforts to increase provider awareness, convey accurate information to the public about Chagas disease and its risks, and improve access to and performance of diagnostic technology and tools.
**Funding:** Limited funding for travel and meetings was provided by the Drugs for Neglected Diseases initiative. N.B. received support from the Mundo Sano Foundation (AWD08818) and Infectious Diseases Society of America Foundation (AWD10100). P.S., N.H., and D.H. received support from Centers for Disease Control Parasitic Diseases Branch for Chagas disease education and screening activities. C.C. and M.E. received funding from Centers for Disease Control Parasitic Diseases Branch for Chagas disease prevention and control activities. M.E. received support from Texas State University for screening of newborns for Chagas disease.

**Conflict of Interests:**

C.B. reports having received royalty payments for topics related to Chagas disease epidemiology, diagnosis and treatment. Y.E.C.S. reports receiving test kit donations from InBios International, Inc. for use in research. M.E. and N.H. report having received honoraria for lectures related to Chagas disease. N.B., C.C., C.F., D.H., N.H., J.M.G., R.G., J.H.M., R.M., S.K.M., P.S.G., and J.W. report no conflicts of interest.

**Previous presentation:** Some aspects of this work were presented at the Second Rethinking Chagas Workshop, Harvard T.H. Chan School of Public Health (virtual), on May 19, 2021 and during IDWeek (September 29-October 3, 2021).

**Acknowledgments**

The authors would like to thank Susan P. Montgomery of the Division of Parasitic Diseases and Malaria of Centers for Disease Control and Prevention (CDC) for invaluable overall guidance and support and immensely helpful comments and suggestions. We are also grateful to Paul Cantey and Barbara Marston of the Division of Parasitic Diseases and Malaria of CDC for their comments on the manuscript. Thanks also to Maria Jesús Pinazo of the Barcelona Institute of Global Health (ISGlobal) and Sergio Sosa-Estani and Louise Burrows of DNDi for their suggestions, and to Hannah Salem of DNDi for help with logistics. DNDi is grateful to its donors, public and private, who have provided funding to DNDi since its inception in 2003. A full list of DNDi donors can be found at [http://www.dndi.org/donors/donors](http://www.dndi.org/donors/donors).
List of Figures

Figure 1: Algorithm for Evaluation of Congenital Chagas Disease for Infants ≤ 3 Months of Age

Source: Centers for Disease Control and Prevention
(https://www.cdc.gov/parasites/chagas/health_professionals/congenital_chagas.html)

Figure 2: Algorithm for Evaluation of Congenital Chagas Disease (CCD) for Infants ≥3 Months of Age

Source: Centers for Disease Control and Prevention
(https://www.cdc.gov/parasites/chagas/health_professionals/congenital_chagas.html)

Figure 3. Algorithm for Screening and Diagnostic Confirmation of T. cruzi Infection in the United States

*There could be rare exceptions, but infection is unlikely in individuals without one of these risk factors.

**Not all commercial labs run a second serological test at this time. Samples should be sent for confirmation to CDC.

***Confirmatory testing for discordant results is available at CDC.

Abbreviations: CD=Chagas disease, Dx=diagnosis, CDC=Centers for Disease Control
References

1. Manne-Goehler J, Umeh CA, Montgomery SP, Wirtz VJ. Estimating the burden of Chagas disease in the United States. PLoS Negl Trop Dis. 2016; 10:e0005033.
2. Bern C, Montgomery SP. An estimate of the burden of Chagas disease in the United States. Clin Infect Dis. 2009; 49:e52-4.
3. Rassi A, Jr., Rassi A, Marin-Neto JA. Chagas disease. Lancet 2010; 375:1388-402.
4. Lee BY, Bacon KM, Bottazzi ME, Hotez PJ. Global economic burden of Chagas disease: a computational simulation model. Lancet Infect Dis 2013; 13:342-8.
5. Manne-Goehler J, Reich MR, Wirtz VJ. Access to care for Chagas disease in the United States: a health systems analysis. Am J Trop Med Hyg 2015; 93:108-13.
6. Perez-Zetune V, Bialek SR, Montgomery SP, Stillwagon E. Congenital Chagas Disease in the United States: The Effect of Commercially Priced Benznidazole on Costs and Benefits of Maternal Screening. Am J Trop Med Hyg 2020; 102:1086-9.
7. Stimpert KK, Montgomery SP. Physician awareness of Chagas disease, USA. EID 2010; 16:2.
8. Pan American Health Organization. Guidelines for the diagnosis and treatment of Chagas disease. Washington, DC: PAHO, 2019.
9. Bern C, Montgomery SP, Herwaldt BL, et al. Evaluation and treatment of Chagas disease in the United States: A systematic review. JAMA 2007; 298:10.
10. Chin-Hong PV, Schwartz BS, Bern C, et al. Screening and treatment of chagas disease in organ transplant recipients in the United States: recommendations from the chagas in transplant working group. Am J Transplant 2011; 11:672-80.
11. Edwards MS, Stimpert KK, Bialek SR, Montgomery SP. Evaluation and Management of Congenital Chagas Disease in the United States. J Pediatric Infect Dis Soc 2019; 8:461-9.
12. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336:924-6.
13. Meymandi SK, Forsyth CJ, Soverow J, et al. Prevalence of Chagas Disease in the Latin American-born Population of Los Angeles. Clin Infect Dis 2017; 64:1182-8.
14. Traina MI, Sanchez DR, Hernandez S, et al. Prevalence and Impact of Chagas Disease Among Latin American Immigrants With Nonischemic Cardiomyopathy in Los Angeles, California. Circ Heart Fail 2015; 8:938-43.
15. Traina MI, Hernandez S, Sanchez DR, et al. Prevalence of Chagas Disease in a U.S. Population of Latin American Immigrants with Conduction Abnormalities on Electrocardiogram. PLoS Negl Trop Dis 2017; 11:e0005244.
16. Park S, Sanchez DR, Traina MI, et al. The Prevalence of Chagas Disease Among Latin American Immigrants with Pacemakers in Los Angeles, California. Am J Trop Med Hyg 2017; 96:1139-42.
17. Kapeluszni L, Varela D, Montgomery SP, et al. Chagas disease in Latin American immigrants with dilated cardiomyopathy in New York City. Clin Infect Dis 2013; 57:e7.
18. Hernandez S, Forsyth CJ, Flores CA, Meymandi SK. Prevalence of Chagas Disease Among Family Members of Previously Diagnosed Patients in Los Angeles, California. Clin Infect Dis 2019; 69:1226-8.
19. Lynn MK, Bossak BH, Sandifer PA, Watson A, Nolan MS. Contemporary autochthonous human Chagas disease in the USA. Acta Trop 2020; 205:105361.
20. Garcia MN, Aguilar D, Gorchakov R, et al. Evidence of autochthonous Chagas disease in southeastern Texas. Am J Trop Med Hyg 2015; 92:325-30.
21. Beatty NL, Klotz SA. Autochthonous Chagas Disease in the United States: How Are People Getting Infected? Am J Trop Med Hyg 2020.
22. Gorchakov R, Trosclair LP, Wozniak EJ, et al. Trypanosoma cruzi Infection Prevalence and Bloodmeal Analysis in Triatomine Vectors of Chagas Disease From Rural Peridomestic Locations in Texas, 2013-2014. J Med Entomol 2016; 53:911-8.
23. Dumonteil E, Pronovost H, Bierman EF, et al. Interactions among Triatoma sanguisuga blood feeding sources, gut microbiota and Trypanosoma cruzi diversity in southern Louisiana. Mol Ecol 2020; 29:3747-61.
24. Beatty NL, Perez-Velez CM, Yaglom HD, et al. Evidence of Likely Autochthonous Transmission of Chagas Disease in Arizona. Am J Trop Med Hyg 2018; 99:1534-6.
25. Franco-Paredes C, Villamil-Gómez WE, Schultz J, et al. A deadly feast: Elucidating the burden of orally acquired acute Chagas disease in Latin America - Public health and travel medicine importance. Travel Med Infect Dis 2020;101565.
26. Sosa-Estani S, Cura E, Velazquez E, Yampotis C, Segura EL. Etiological treatment of young women infected with Trypanosoma cruzi, and prevention of congenital transmission. Rev Soc Bras Med Trop 2009; 42:484-7.
27. Wheelock AE, Sandhu SK, Loskill AJ, et al. Testing for Chagas disease in an at-risk population. J Card Fail 2021; 27:109-11.
28. Gray EB, La Hoz RM, Green JS, et al. Reactivation of Chagas disease among heart transplant recipients in the United States, 2012-2016. Transpl Infect Dis 2018; 20:e12996-e.
29. Bern C. Chagas disease in the immunosuppressed host. Curr Opin Infect Dis 2012; 25:450-7.
30. Centers for Disease Control. Congenital Chagas Disease. Available at: https://www.cdc.gov/parasites/chagas/health_professionals/congenital_chagas.html. Accessed January 24 2020.
31. Carlier Y, Altcheh J, Anghelen A, et al. Congenital Chagas disease: Updated recommendations for prevention, diagnosis, treatment, and follow-up of newborns and siblings, girls, women of childbearing age, and pregnant women. PLoS Negl Trop Dis 2019; 13:e0007694.
32. Alonso-Vega C, Billot C, Torrico F. Achievements and challenges upon the implementation of a program for national control of congenital Chagas in Bolivia: results 2004-2009. PLoS Negl Trop Dis 2013; 7:e2304.
33. Chippaux JP, Clavijo AN, Santalla JA, Postigo JR, Schneider D, Brutus L. Antibody drop in newborns congenitally infected by Trypanosoma cruzi treated with benznidazole. Trop Med Int Health : TM & IH 2010; 15:87-93.
34. Bern C, Martin DL, Gilman RH. Acute and congenital Chagas disease. Adv Parasitol 2011; 75:19-47.
35. Bern C, Verastegui M, Gilman RH, et al. Congenital Trypanosoma cruzi transmission in Santa Cruz, Bolivia. Clin Infect Dis 2009; 49:1667-74.
36. Messenger LA, Gilman RH, Verastegui M, et al. Toward Improving Early Diagnosis of Congenital Chagas Disease in an Endemic Setting. Clin Infect Dis 2017; 65:268-75.
37. Murcia L, Carrilero B, Munoz-Davila MJ, Thomas MC, Lopez MC, Segovia M. Risk Factors and Primary Prevention of Congenital Chagas Disease in a Nonendemic Country. Clin Infect Dis 2012; 56:496-502.
38. Whitman JD, Bulman CA, Gunderson EL, et al. Chagas Disease Serological Test Performance in U.S. Blood Donor Specimens. J Clin Microbiol 2019; 57:e01217-19.
39. Edwards MS, Rench MA, Todd CW, et al. Perinatal Screening for Chagas Disease in Southern Texas. Jo Ped Infect Dis Soc 2013; 4:67-70.
40. Castro-Sesquen YE, Saldaña A, Patino Nava D, et al. Use of a Latent Class Analysis in the diagnosis of chronic Chagas disease in the Washington Metropolitan area. Clin Infect Dis 2020.
41. Verani JR, Seitz A, Gilman RH, et al. Geographic Variation in the Sensitivity of Recombinant Antigen-based Rapid Tests for Chronic Trypanosoma cruzi Infection. Am J Trop Med Hyg 2009; 80:410-5.
42. Caballero EZ, Correa R, Nascimento MS, Villarreal A, Llanes A, Kesper N, Jr. High sensitivity and reproducibility of in-house ELISAs using different genotypes of Trypanosoma cruzi. Parasite Immunol 2019; 41:e12627.
43. Truyens C, Dumonteil E, Alger J, et al. Geographic variations in test reactivity for the serological diagnosis of Trypanosoma cruzi infection. J Clin Microbiol 2021; Jcm0106221.
44. Messenger LA, Miles MA, Bern C. Between a bug and a hard place: Trypanosoma cruzi genetic diversity and the clinical outcomes of Chagas disease. Expert Rev Anti Infect Ther 2015; 13:995-1029.
45. Centers for Disease Control. American Trypanosomiasis. Available at: https://www.cdc.gov/dpdx/trypanosomiasisAmerican/index.html. Accessed September 28 2020.
46. Umezawa ES, Nascimento MS, Kesper N, Jr., et al. Immunoblot assay using excreted-secreted antigens of Trypanosoma cruzi in serodiagnosis of congenital, acute, and chronic Chagas’ disease. J Clin Microbiol 1996; 34:2143-7.
47. U.S. Food and Drug Administration. Laboratory Developed Tests. Available at: https://www.fda.gov/medical-devices/vitro-diagnostics/laboratory-developed-tests. Accessed November 3 2020.
48. Pérez-Molina JA, Molina I. Chagas disease. Lancet 2018; 391:82-94.
49. Nunes MCP, Beaton A, Acquatella H, et al. Chagas Cardiomyopathy: An Update of Current Clinical Knowledge and Management: A Scientific Statement From the American Heart Association. Circ 2018; 138:e169-e209.
50. Pinazo MJ, Cañas E, Elizalde JI, et al. Diagnosis, management and treatment of chronic Chagas’ gastrointestinal disease in areas where Trypanosoma cruzi infection is not endemic. Gastroenterol Hepatol 2010; 33:191-200.
### Table 1. Studies on Prevalence of Chagas Disease in Latin American-born Populations in the U.S. (2010-2020)*

| Study           | Population                                                                 | Prevalence (%) |
|-----------------|-----------------------------------------------------------------------------|----------------|
| Castro et al. 2020 | 1,514 people in the greater Washington, DC metropolitan area (community screening program) | 3.8            |
| Hernandez et al. 2019 | 189 relatives of 86 previously diagnosed patients with CD                  | 7.4            |
| Manne-Goehler et al. 2019 | 5,125 people from endemic regions screened in primary care setting in East Boston | 1.0            |
| Meymandi et al. 2017 | 4,755 Latin American-born residents of Los Angeles (community screening program) | 1.2            |
| Traina et al. 2017 | 327 hospital patients with electrocardiogram abnormalities               | 5.2            |
| Park et al. 2017 | 80 patients with pacemakers                                                | 7.5            |
| Traina et al. 2015 | 135 hospital patients with nonischemic cardiomyopathy                     | 19.0           |
| Kapeluszni et al. 2013 | 39 hospital patients with nonischemic cardiomyopathy                    | 13.0           |

*All study populations consist of people who were born or lived a significant amount of time in endemic countries of Latin America.
Table 2: Key studies, congenital transmission of Chagas disease in the United States

| Study                      | Key finding                                                                                                                                                                                                 |
|----------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| *Perez-Zetune et al. 2020*| In the US, congenital Chagas disease screening is cost saving for all rates of congenital transmission $\geq 0.001\%$ and all levels of maternal prevalence $\geq 0.06\%$. Targeted screening saves $1,314$ per birth.                                      |
| *Yarrington et al. 2019*  | 0.5\% prevalence in screening of 619 Latina* pregnant women in East Boston.                                                                                                                                   |
| *Edwards et al. 2015*     | 0.25\% prevalence in screening of 4,000 Latina* mothers in Texas at delivery                                                                                                                                    |
| *CDC 2012*                | First U.S. documented case of congenital Chagas disease in Virginia                                                                                                                                         |
| *Di Pentima et al. 1999*  | 0.3\% prevalence in screening of 3,765 pregnant women in Houston (Latina and non-Latina)                                                                                                                     |

* “Latina” refers to ethnicity, not necessarily birth in a Chagas disease-endemic country in Latin America.
| Test                        | Antigen (51)                                      | Availability                                      | Manufacturer                                      |
|-----------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|
| Hemagen ELISA               | Purified antigens from parasite culture           | Commercially available                            | Hemagen Diagnostics, Columbia, MD                 |
| InBios Chagas Detect Plus   | Recombinant multiepitope fusion antigen           | Commercially available point-of-care test         | InBios International, Inc., Seattle, WA           |
| Ortho *T. cruzi* ELISA      | Purified antigens from parasite culture           | Not commercially available for diagnostic use; only marketed for blood and organ donor screening | Ortho Clinical Diagnostics, Inc., Raritan, NJ     |
| Wiener Chagatest ELISA      | Recombinant trypomastigote-shed acute-phase antigens | Commercially available                            | Wiener Lab Group, Rosario, Argentina              |

* As of June, 2021
Table 4. Recommendations for Screening and Diagnosis of Chagas Disease in the United States

| Recommendation                                                                 | Strength | Quality of evidence |
|-------------------------------------------------------------------------------|----------|---------------------|
| **Who should be screened for Chagas disease in the United States?**           |          |                     |
| People who were born or lived for a prolonged period (> 6 months) in areas of Mexico, Central or South America with endemic Chagas disease. | strong   | low                 |
| Close (first-degree) relatives of people previously diagnosed with Chagas disease | strong   | low                 |
| People with entomologically confirmed or highly suspected exposure (bites and/or triatomines/kissing bugs found in the home), in states with known presence of triatome species capable of transmitting *T. cruzi* | conditional | low                 |
| Travelers with confirmed exposure to triatomines or associated risk factors in regions of Latin America where Chagas disease is endemic | conditional | low                 |
| Women of childbearing age who have lived in a region of Mexico, South or Central America with endemic Chagas disease | strong   | moderate            |
| **Which clinical conditions warrant diagnostic testing for Chagas disease in people from endemic countries of Latin America?** |          |                     |
| ECG abnormalities suggestive of infection, even in the absence of symptoms. These include first degree atrioventricular block, premature ventricular contractions, atrial fibrillation, right bundle branch block, left anterior fascicular block, bifascicular block, and low voltage QRS | strong   | low                 |
| Bradyarrhythmias and tachyarrhythmias                                         | strong   | low                 |
| Regional wall motion abnormalities (particularly basal inferolateral, apical aneurysm) | strong   | low                 |
| Thromboembolic phenomenon                                                     | strong   | low                 |
| Congestive heart failure and/or a reduced ejection fraction                   | strong   | low                 |
| Megacolon/megaesophagus                                                       | strong   | low                 |
| **What is the diagnostic algorithm for testing neonates and infants (<1 year old) who are born to infected mothers?** |          |                     |
| Infants in whom congenital Chagas disease is suspected should undergo evaluation using existing CDC-based recommendations | strong   | moderate            |
| **What is the recommended algorithm for diagnosing Chagas disease in the United States?** |          |                     |
| Diagnostic testing for chronic *T. cruzi* infection should be conducted using two distinct assays based on different antigens or in different | strong   | moderate            |
formats following Pan American Health Organization (PAHO) and CDC guidelines. If the results are discordant, a third distinct test should be performed. Confirmed diagnosis requires positive results by at least two tests.

| Screening by clinical and public health laboratories in populations with low T. cruzi infection prevalence should be conducted using a high sensitivity test, bearing in mind the anticipated false positive rate of (1 – specificity). Individuals with positive results by the screening test require confirmatory testing as outlined in the above recommendation | strong | moderate |

What is the next step after a patient has a confirmed diagnosis of Chagas disease?

Even if asymptomatic, individuals who test positive for T. cruzi infection should receive:

| Test                  | Strength | Sensitivity |
|-----------------------|----------|-------------|
| Electrocardiogram     | strong   | high        |
| Echocardiogram        | strong   | low         |
| Chest x-ray           | strong   | low         |
Algorithm for Evaluation of Congenital Chagas Disease: Infant <3 Months of Age*

At time of birth, test cord blood (if no maternal blood contamination) or whole blood from infant for:
- Microscopic examination of blood (Giemsa stain for T. cruzi trypomastigotes)
- PCR
- Chagas disease serology if mother not tested during pregnancy to detect maternal antibody and determine whether infant at risk

Giemsa stain or PCR positive?  
- Yes
  - Evaluate the infant for treatment
- No
  - Repeat microscopic examination of blood smear and PCR at 4–6 weeks of age. Giemsa stain or PCR positive?
    - Yes
      - Evaluate the infant for treatment
    - No
      - Serology when infant 9–12 months of age
        - Serology positive
          - Evaluate the infant for treatment
        - Serology negative
          - CCD excluded

*Infant born to mother with suspected or confirmed Chagas disease OR infant with symptoms of congenital Chagas disease in at-risk mother with serologic status unknown.
Algorithm for Evaluation of Congenital Chagas Disease (CCD) for Infants ≥3 Months of Age

Infant is ≥3 months of age and born to a mother with Chagas disease?

- Yes
  - Screen sample of infant serum for *T. cruzi* antibody
    - Positive?
      - Yes
        - Obtain confirmatory *T. cruzi* serologic testing when infant is 9–12 months of age
          - Positive?
            - Yes
              - Evaluate patient for treatment
            - No
              - CCD excluded
          - No
            - CCD excluded
      - No
        - CCD excluded
Figure 3

One or more risk factors? (Ranked in importance)
1. Born in or lived >6 months in an endemic country (mainland Latin America)
2. Having a family member with CD
3. Lived in housing made of natural materials (mud, adobe, thatch, palm leaves) in Latin America
4. Being bitten by kissing bugs or finding kissing bugs in the home

Yes
Screen

No
Risk negligible

Testing probably not needed

Screening
Sero logical assay*

Positive
Negative

Negative Dx

Second test
Different serological assay**

Positive
Negative

Third test***
CDC or other lab

Positive
Negative

Positive Dx

-electrocardiogram
-echocardiogram
Evaluate treatment options